JP2011520917A5 - - Google Patents

Info

Publication number

JP2011520917A5

JP2011520917A5 JP2011509781A JP2011509781A JP2011520917A5 JP 2011520917 A5 JP2011520917 A5 JP 2011520917A5 JP 2011509781 A JP2011509781 A JP 2011509781A JP 2011509781 A JP2011509781 A JP 2011509781A JP 2011520917 A5 JP2011520917 A5 JP 2011520917A5

Authority

JP

Japan

Prior art keywords

heart failure

subject

treatment

relaxin

medicament

Prior art date

2009-05-15

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 206010019280 Heart failures Diseases 0.000 claims 13
• 108090000103 Relaxin Proteins 0.000 claims 8
• 102000003743 Relaxin Human genes 0.000 claims 8
• 239000003814 drug Substances 0.000 claims 6
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 4
• 238000004519 manufacturing process Methods 0.000 claims 4
• 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 2
• 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims 2
• 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 2
• 206010007556 Cardiac failure acute Diseases 0.000 claims 2
• PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims 2
• 239000008280 blood Substances 0.000 claims 2
• 210000004369 blood Anatomy 0.000 claims 2
• 230000000747 cardiac effect Effects 0.000 claims 2
• 229940109239 creatinine Drugs 0.000 claims 2
• HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims 2
• 230000036581 peripheral resistance Effects 0.000 claims 2
• 230000002685 pulmonary effect Effects 0.000 claims 2
• 230000036593 pulmonary vascular resistance Effects 0.000 claims 2
• 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
• 229940127218 antiplatelet drug Drugs 0.000 claims 1
• 239000002876 beta blocker Substances 0.000 claims 1
• 229940097320 beta blocking agent Drugs 0.000 claims 1
• 239000002934 diuretic Substances 0.000 claims 1
• 230000001882 diuretic effect Effects 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
• 230000035488 systolic blood pressure Effects 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 claims 1